“Bear-Pit Session” Highlights Peterson Capital’s Canada Growth Conference in Montreal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2025
0mins
Source: Globenewswire
Conference Highlights: The Canada Growth Conference in Montreal featured a "Bear Pit" session where nine CEOs engaged in dynamic Q&A with investors, receiving positive feedback for their presentations and insights. Eupraxia Pharmaceuticals was recognized as the Top Growth Story of the event.
Future Events: Peterson Capital announced plans for a follow-up conference in Dublin, Ireland, scheduled for September 25-27, 2025, aimed at fund managers and family offices from the UK and Europe, showcasing ten of its public company clients.
Analyst Views on EPRX
Wall Street analysts forecast EPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EPRX is 13.02 USD with a low forecast of 11.02 USD and a high forecast of 16.03 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.010
Low
11.02
Averages
13.02
High
16.03
Current: 9.010
Low
11.02
Averages
13.02
High
16.03
About EPRX
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
